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Objective: In 2001, the Korean College of Neuropsychopharmacology and the Korean Society for Schizophrenia Research 
developed the Korean Medication Algorithm Project for Schizophrenia (KMAP-SPR 2001, revised 2006) through a con-
sensus of expert opinion. The present study was carried out to support the second revision of the KMAP-SPR.
Methods: Based on clinical guidelines and studies on the treatment of psychotic symptoms in schizophrenia, the 
Executive committee completed a draft of KMAP-SPR 2019. To obtain an expert consensus, a Review committee of 
100 Korean psychiatrists was formed and 69 responded to a 30-item questionnaire. Based on their responses, the 
KMAP-SPR 2019 was finalized. 
Results: The revised schizophrenia algorithm now consists of 5 stages. At Stage 1, monotherapy with atypical anti-
psychotics was recommended by expert reviewers as the first-line strategy. At Stage 2, most reviewers recommended 
the use of typical or atypical antipsychotic drugs not used at Stage 1. At Stage 3, many reviewers agreed with the 
administration of clozapine. At Stage 4, a combination of clozapine and other agents such as antipsychotics, mood 
stabilizers, antidepressants, or electroconvulsive therapy was recommended. At Stage 5, most reviewers recommended 
combined treatment with an antipsychotic other than clozapine; and a mood stabilizer, antidepressant, or electro-
convulsive therapy. At any stage, prescribing long-acting injectable antipsychotics at the discretion of the clinician was 
recommended.
Conclusion: Compared with previous versions, the KMAP-SPR 2019 now recommends using clozapine earlier in treat-
ment-refractory schizophrenia. In addition, the use of long-acting injectable antipsychotics is now considered to be 
available at any stage.
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INTRODUCTION
Medication algorithms can help clinicians make deci-
sions by providing a wealth of information about psycho-
tropic medications and research data [1]. Although treat-
ment algorithms and clinical practice guidelines have 
been published in many countries, the guidelines for 
pharmacological treatment can vary from country to 
country because national health systems, economic sit-
uations, and cultural environments can differ. Most medi-
cation algorithms rely on the evidence of randomized 
controlled trials, but incorporating expert consensus is al-
so important because this can lead to an algorithm re-
flective of national characteristics [2,3].
In order to develop medication algorithms suitable for 
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clinical situations in Korea, the Korean College of Neuro-
psychopharmacology (KCNP) and the Korean Society for 
Schizophrenia Research (KSSR) developed the Korean 
Medication Algorithm Project for Schizophrenia (KMAP-SPR) 
through a consensus of expert opinion in 2001, which 
was updated in 2006. However, since the publication of 
KMAP-SPR 2006, several international clinical guidelines 
have been revised [4-9], new antipsychotic drugs have 
been developed [10-12], and studies have been pub-
lished supporting the use of long-acting injectable anti-
psychotics (LAIs) in first-episode schizophrenia [13]. 
Accordingly, the KCNP and KSSR have now created a sec-
ond revision, the KMAP-SPR 2019, to reflect changes in 
expert opinion regarding the treatment of psychotic symp-
toms in patients with schizophrenia. 
Common to the KMAP-SPR series is a three-part organ-
ization: 1) treatment of psychotic symptoms, 2) treatment 
of comorbidities, and 3) treatment of adverse effects from 
antipsychotic medication. We aimed to determine an ex-
pert consensus on a draft revision of KMAP-SPR that re-
flected developments since 2006, for incorporation into a 
finalized second revision, with emphasis on Part 1). 
METHODS
Executive Committee
This committee performs several practical tasks for 
medication algorithm development. There are two chair-
persons, one of whom is head director of the KCNP and 
the other, head director of the KSSR. In addition to the 
chairpersons, the Committee includes three KCNP mem-
bers and four KSSR members. The Executive committee 
recruits the members of the Review committee. 
The Executive committee completed a draft version of 
KMAP-SPR 2019 based on various clinical guidelines and 
on published studies on the treatment of psychotic symp-
toms in schizophrenia. To gather expert opinion, they al-
so wrote a questionnaire about the draft version and cir-
culated it to the Review committee for comments. 
Review Committee
The Executive committee recruited 100 Korean psy-
chiatrists who were life-long members of KCNP or KSSR 
and had more than 10 years of clinical experience in the 
field of schizophrenia. Through discussion, candidates 
who were considered clinically and investigationally ex-
perienced in the field were selected by the Executive 
committee. The questionnaire was mailed to members of 
this committee and responses were received from 69 
(69.0%) members. The respondents worked in a wide va-
riety of clinical settings, including university hospitals (n = 
50), general/psychiatric hospitals (n = 17), and private 
psychiatric clinics (n = 2). 
Questionnaire
The KMAP-SPR 2019 questionnaire was similar to that 
used to develop the KMAP-SPR 2006, with some 
modifications. To take advantage of both evidence-based 
and expert-consensus guidelines, the questionnaire was 
structured as requests for comments on the draft of KMAP-SPR 
2019, which was based only on evidence at that stage. 
Specifically, the questions asked how satisfied the re-
viewers were with the treatments recommended at each 
stage, or what treatments they would prefer. Degree of sat-
isfaction was measured on a five-point scale. Five in-
dicated “very satisfied,” 4 indicated “usually satisfied”, 3 
indicated “moderate”, 2 indicated “usually unacceptable” 
and 1 indicated “absolutely unacceptable”. In questions 
answered with 1 or 2 points, the reviewers were asked to 
give their recommendations as free-form statements. The 
questionnaire had 30 questions. Fifteen concerned either 
the overall composition of the medication algorithm or 
the treatment of psychotic symptoms, and the remainder 
concerned treatment of comorbidities and adverse effects. 
The new modifications of the questionnaire were: In Stage 
1, the Executive committee proposed monotherapy with 
second-generation antipsychotics (SGAs) as the first-line 
treatment, and asked the reviewers which SGA they 
prefer. In Stage 4, the Executive committee proposed as 
the treatment of choice a combination therapy consisting 
of clozapine plus other treatments such as first-generation 
antipsychotics (FGAs), SGAs, mood stabilizers, anti-
depressants, or nonpharmacological treatments such as 
electroconvulsive therapy (ECT). The reviewers were also 
asked which treatment option they would prefer to com-
bine with clozapine. 
Public Hearing
On April 20, 2018, at the Spring Conference of the 
Korean Society for Neuropsychiatry, a public hearing for 
the development of the KMAP-SPR 2019 was held. 
Various proposals raised at the hearing were reviewed by 
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Fig. 1. Korean Medication Algorithm for Schizophrenia 2019: treatment of psychotic symptoms. 
SGA, second generation antipsychotics; LAI, long-acting injectable antipsychotics; FGA, first generation antipsychotics; ECT; electroconvulsive therapy.
aOther SGAs including olanzapine, amisulpride, quetiapine, ziprasidone, paliperidone, blonanserin, zotepine are approved and used currently in 
South Korea. bDepending on the clinical situation, it is possible to move to Stage 5 at any Stage. cDepending on the clinical judgment, LAI can be 
considered at any Stage; Depending on the clinical situation, it is possible to skip to the further stage.
the Executive committee and the KMAP-SPR 2019 was 
then finalized. 
Data Analysis and Development of Medication 
Algorithms
For each question, we counted how many reviewers 
gave particular scores. If a question received more than 4 
points, it was considered that the reviewer was generally 
satisfied with the treatment option being proposed. If 
more than 50% of the respondents gave more than 4 
points, it implies that the reviewers reached a consensus 
on the question. Recommendations at each stage were 
based on a draft prepared by the Executive committee 
based on various clinical guidelines and published stud-
ies, but amendments have been made if expert consensus 
was not reached on a particular item.
Ethics
The present study was conducted according to the 
Declaration of Helsinki. All reviewers received a pre-
determined fee for their participation. 
RESULTS
Overview
As shown in Figure 1, the medication algorithm for 
treatment of psychotic symptoms consists of five stages. In 
order not to limit clinical judgment, however, clinicians 
can skip a stage depending on the clinical situation. As far 
as possible, antipsychotic monotherapy is recommended. 
The new parts of the KMAP-SPR 2019 are revisions to 
Stage 2 and the criteria for LAIs (Table 1). 
Stage 1
The Executive committee had proposed SGA mono-
therapy as the first-line treatment for psychotic symptoms. 
In addition, they had proposed LAIs at Stage 1 if tolerance 
to oral medication is demonstrated. The reviewers fa-
vored risperidone (29.9%), aripiprazole (28.4%), olanza-
pine (16.4%), and paliperidone (14.9%) for SGA mono-
therapy at Stage 1 (Table 2). 
Stage 2
The Executive committee had proposed that if there is 
no response to the SGA selected at Stage 1, another SGA 
or FGA monotherapy can be tried at Stage 2. Of the 69 re-
viewers who answered the question for Stage 2, 62 were 
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Table 1. Comparisons of treatment strategies for psychotic symptoms between the Korean Medication Algorithm for Schizophrenia 2006 and 2019
First revision in 2006 Second revision in 2019
Stage 1 SGA SGA
Stage 2 SGA (not tried in Stage 1) or FGA
With no response to a single trial of SGA or FGA, another trial 
of a different generation antipsychotic drug can be done
SGA (not tried in Stage 1) or FGA
With no response to a single trial of SGA or FGA, proceed 
to Stage 3
Stage 3 Clozapine Clozapine
Stage 4 Clozapine ＋ other agent (FGA/SGA, MS, ECT, etc.) Clozapine ＋ other agent (FGA/SGA, MS, ECT, etc.)
Stage 5 Combination therapy Combination therapy
LAI No response due to non-compliance Depending on the clinical judgment
SGA, second generation antipsychotics; FGA, first generation antipsychotics; MS, mood stabilizer; ECT, electroconvulsive therapy; LAI, long-acting 
injectable antipsychotics. 
Table 3. Preference of combination strategies for Stage 4
Strategies Preference rate 
Clozapine ＋ SGA 91.0%
Clozapine ＋ MS 6.0%
Clozapine ＋ ECT 1.5%
Clozapine ＋ LAI 1.5%
SGA, second generation antipsychotics; MS, mood stabilizer; ECT, 
electroconvulsive therapy; LAI, long-acting injectable antipsychotics. 
Table 2. Preference rate and ranking of antipsychotics for Stage 1 
Antipsychotics First place Second place Third place
Risperidone 29.9% (1) 14.9% (4) 10.4% (4)
Aripiprazole 28.4% (2) 16.4% (3) 25.4% (1)
Olanzapine 16.4% (3) 34.3% (1) 13.4% (3)
Paliperidone 14.9% (4) 17.9% (2) 9.0% (6)
Blonanserin 4.5% (5) 1.5% (7) 3.0% (7)
Amisulpride 3.0% (6) 6.0% (5) 23.9% (2)
Quetiapine 3.0% (7) 6.0% (5) 10.4% (4)
Ziprasidone - - 1.5% (8)
Data are presented as preference rate (ranking). 
-, not available.
Table 4. Preference of atypical antipsychotics for Stage 4
Antipsychotics First place Second place Third place
Amisulpride 36.5% (1) 26.0% (2) 20.0% (2)
Aripiprazole 32.7% (2) 28.0% (1) 17.8% (3)
Risperidone 23.1% (3) 12.0% (4) 28.9% (1)
Paliperidone 5.8% (4) 20.0% (3) 8.9% (5)
Olanzapine 1.9% (5) 6.0% (5) 6.7% (6)
Quetiapine - 6.0% (5) -
Blonanserin - 2.0% (7) 11.1% (4)
Ziprasidone - 6.7% (6)
Data are presented as preference rate (ranking). 
-, not available.
satisfied (usually satisfied 37, very satisfied 25). According 
to the KMAP-SPR 2006, if there is no response to a single 
trial of SGA or FGA, another different-generation anti-
psychotic drug can be tried. However, according to the 
KMAP-SPR 2019, if there is no response to a single trial of 
SGA or FGA monotherapy, proceeding to Stage 3 is 
recommended. 
Stage 3
The Executive committee had proposed clozapine 
monotherapy as the treatment of choice at Stage 3. Of the 
69 reviewers who answered the question for Stage 3, 48 
were satisfied (usually satisfied 45, very satisfied 3). Because 
there should be no response to two adequate trials of anti-
psychotic drugs before proceeding to Stage 3, reaching 
Stage 3 can be considered treatment resistance. When 
asked whether to test serum clozapine levels at this point, 
35 out of 67 respondents (52.2%) were opposed. 
Stage 4
The Executive committee had proposed that when pa-
tients do not show an adequate response to clozapine, 
combination therapy with clozapine plus other treat-
ments is the treatment of choice. The other agents are 
FGA, SGA, mood stabilizers, antidepressants, or non-
pharmacological treatments such as ECT. As shown in 
Table 3, 91.0% of reviewers preferred a combination of 
clozapine and an SGA at this stage. The SGAs most pre-
ferred for combination with clozapine were amisulpride 
(36.5%), aripiprazole (32.7%), and risperidone (23.1%) 
(Table 4). 
Stage 5
The Executive committee had proposed that there is no 
treatment of choice for treatment-resistant patients who 
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refuse to take clozapine or who do not respond to clozapine. 
Therefore, at Stage 5, various combination therapies in-
cluding an SGA combined with an FGA, a combination of 
SGAs, an FGA/SGA with ECT, or an FGA/SGA combined 
with another agent (e.g., mood stabilizer, antidepressant) 
can be tried. Of the 69 reviewers who answered the ques-
tion for Stage 5, 60 were satisfied (usually satisfied 43, 
very satisfied 17).
LAIs
In the KMAP-SPR 2006, LAIs were recommend only in 
cases of no treatment response due to drug non-com-
pliance. The draft revision recommended that LAIs be pre-
scribed at any stage at the clinician’s discretion after toler-
ance to oral medication is verified. Of the 69 reviewers 
who answered the question on LAIs, 59 were satisfied 
(usually satisfied 27, very satisfied 32).
Switching Strategy
The Executive committee had proposed that the pre-
ferred switching strategy be “overlap and taper,” which 
means continuing the same dose of the first antipsychotic 
while gradually increasing that of the second to a ther-
apeutic level and then tapering the first. Of the 69 re-
viewers who answered the question on switching strategy, 
55 were satisfied (usually satisfied 49, very satisfied 6).
DISCUSSION
Evidence-based vs. Consensus-based Guidelines
Guidelines on treatment fall into two types: expert con-
sensus and evidence-based, each with advantages and 
disadvantages. The consensus among experts has the ad-
vantage of reflecting national characteristics such as 
health care policy, the economic situation, and ethnicity. 
Expert consensus statements can also provide practice- 
based evidence in the absence of high-quality research 
evidence. However, expert-consensus guidelines have in 
common a difficulty in guaranteeing validity. On the oth-
er hand, most evidence-based guidelines rely on random-
ized controlled trials (RCTs) with strict inclusion and ex-
clusion criteria that apply only to the specific populations 
so defined, and conclusions from RCTs often cannot be 
generalized to the diverse populations seen in clinical 
practice. The present guideline is based mostly on expert 
consensus, but the recommendations for Stage 1 and 
Stage 4 are based on new research. Since this guideline 
combines expert consensus with research evidence, it will 
be necessary to make further revisions if warranted by 
new knowledge, new high-level evidence, or experience 
over time, all of which must be monitored on an ongoing 
basis. 
Stage 1
As in the KMAP-SPR 2001 and 2006, SGA mono-
therapy is the first-line treatment strategy for psychotic 
symptoms in the KMAP-SPR 2019. It has been widely ac-
cepted that SGAs should be used as the first-line drug. 
However, paradigms changed after some large-scale stud-
ies such as Clinical Antipsychotic Trials for Intervention 
Effectiveness (CATIE) [14] and Cost Utility of the Latest 
Antipsychotic drugs in Schizophrenia Study (CUtLASS) 
[15] emphasized that certain SGAs are not superior to cer-
tain FGAs regarding effectiveness. Despite these findings, 
we decided to use SGA as the first-line treatment for the 
following two reasons: First, FGAs have a high risk of ex-
trapyramidal side effects. These side effects are one of the 
major causes of poor drug compliance and decreased 
quality of life [16,17]. In particular, FGAs are known to 
produce numerous irreversible side effects such as tardive 
dyskinesia, as well as life-threatening side effects such as 
neuroleptic malignant syndrome. At present, the most im-
portant known principle for preventing tardive dyskinesia 
is to minimize exposure to FGAs. Second, a meta-analysis 
showed that SGAs were superior to FGAs regarding re-
lapse prevention [18]. 
Stage 2
According to the KMAP-SPR 2006, after a single trial of 
an SGA or FGA, another antipsychotic of a different gen-
eration can be tried, but in the KMAP-SPR 2019, a single 
trial of any SGA or FGA is recommended at Stage 2. This 
is consistent with other clinical guidelines such as the 
Schizophrenia Patient Outcomes Research Team (PORT) 
psychopharmacological treatment recommendations [4], 
The World Federation of Societies of Biological Psychiatry 
(WFSBP) guidelines for biological treatment of schizo-
phrenia [6], The National Institute for Health and Care 
Excellence (NICE) guideline [9], and The Royal Australian 
and New Zealand College of Psychiatrists clinical prac-
tice guideline [7], which recommends a trial of clozapine 
if there is no response to two trials of different antipsychotics. 
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In the KMAP-SPR 2006, the use of FGAs at Stage 2 was 
limited to patients who had shown a good response to 
FGAs in the past. However, since CATIE and CUtLASS 
have shown that the difference in treatment effects be-
tween SGA and FGA may not be significant, whether to 
use FGAs at Stage 2 is left to the judgment of the clinician. 
Stage 3
If no treatment response is achieved at Stage 2, cloza-
pine monotherapy is recommended at Stage 3. Treatment 
resistance is usually defined when patients with schizo-
phrenia continue to experience clinically significant psy-
chotic symptoms after 2 adequate trials of different anti-
psychotics [19]. Moreover, almost all clinical guidelines 
[4-9] suggest that clozapine be offered to patients with 
treatment-resistant schizophrenia, and this is consistent 
with KMAP-SPR 2019. Many clinical guidelines recom-
mend the determination of clozapine plasma levels to 
guide dosage and check drug compliance, but more than 
half of the reviewers objected to monitoring clozapine 
levels. This is probably because of limited availability of 
testing; clozapine plasma level monitoring is not im-
plemented in many hospitals in South Korea. 
Stage 4
At Stage 4, a combination of an SGA and clozapine was 
the most preferred treatment. This is consistent with a re-
cent meta-analysis, which demonstrated that this combi-
nation is modestly beneficial in patients not responding to 
clozapine alone [20]. However, little evidence was found 
for preferring one SGA over another in combination with 
clozapine. The reviewers preferred amisulpride, aripipra-
zole, and risperidone. In other research, patients who 
were only partially responsive to clozapine monotherapy 
and who received amisulpride or placebo for 6 weeks 
showed the beneficial effect of augmented amisulpride in 
the secondary measures (e.g., Clinical Global Impression) 
[21]. In a study comparing the effectiveness of cloza-
pine/amisulpride and clozapine/quetiapine in patients 
partially responsive to clozapine, the improvement asso-
ciated with amisulpride was significantly greater than that 
seen with quetiapine [22]. When clozapine was com-
bined with aripiprazole, researchers observed an im-
provement in negative symptoms [23], or a significant im-
provement in positive symptoms and general psychopa-
thology [24]. Studies on the combination of clozapine 
with risperidone were reported most often, but findings 
have been mixed: significant improvement [25,26] or no 
proven improvement [27-29]. 
Stage 5
Little evidence is available to support combinations of 
non-clozapine antipsychotics [30], although this is com-
mon in clinical practice. Since controlled studies on com-
bination therapy are by nature difficult to conduct, few 
studies have reported on combinations of antipsychotics 
other than those involving clozapine in treatment resistant 
schizophrenia [30]. At Stage 5, an SGA/FGA plus ECT, or 
an SGA/FGA plus another agent such as a mood stabilizer 
can be tried, but these treatments are likewise not based 
on controlled studies. However, the effects of treatment 
are believed to vary considerably across individuals, in-
volving substantial improvement in some and worsening 
in others, although proven evidence for this is lacking. 
Because polypharmacy is a risk factor for severe side-ef-
fect burden [31], caution should be exercised in prescrib-
ing more than three kinds of drugs despite no apparent 
therapeutic benefit. 
LAIs
In the KMAP-SPR 2006, LAIs were used in cases of poor 
drug compliance, but the KMAP-SPR 2019 allows clini-
cians to use it at their discretion. This recommendation is 
based on the advantages of LAIs over oral antipsychotics, 
namely improved compliance to medication and pre-
vention of the worsening of symptoms and relapses asso-
ciated with the discontinuation of treatment [13]. Non- 
compliance is very common during the early stages of 
treatment; approximately 40% of patients stop taking their 
antipsychotic medication within 1 year and about 75% 
stop taking the medication within 2 years [32]. In patients 
with schizophrenia, non-compliance is problematic be-
cause it can lead to exacerbation of symptoms and relap-
ses [33]. LAIs is an important treatment option to compen-
sate for non-compliance by making it easier to detect 
non-compliance and by enabling early intervention [34]. 
Several meta-analyses demonstrated that LAIs were supe-
rior to oral antipsychotics in preventing rehospitalization 
and relapse [35,36]. Furthermore, a study of patients with 
first-episode schizophrenia showed that LAIs were asso-
ciated with significantly lower relapse and rehospitaliza-
tion rates than those of oral antipsychotics [37].
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Advantages and Limitations
Several limitations of this study should be acknowledged. 
First, the study is based on a consensus of Korean experts 
rather than experimental evidence. Most available evi-
dence is from RCTs. However, RCTs may not apply to re-
al-life clinical situations because they have strict in-
clusion/exclusion criteria and highly controlled settings. 
Therefore, we drafted the revision with reference to recent 
clinical studies and other guidelines based on ex-
perimental evidence, but we also consulted with experts 
to ensure that the algorithm reflected actual clinical 
situations. Second, the size of the Review committee may 
be too small to provide a valid consensus by some criteria. 
However, we decided that a sample of 69 psychiatrists is 
sufficient based on the fact that there are only 4,525 psy-
chiatrists in South Korea. Third, the draft algorithm made 
no distinction between first-episode and multiple-episode 
patients. Because these two kinds of patient have different 
treatment outcomes and clinical features, several guide-
lines provide different treatment recommendations for 
first- and multiple-episode patients [6,7]. This option should 
be considered in future KMAP-SPR revisions.
To our knowledge, the KMAP-SPR 2019 is the most re-
cent guideline revision based on both recent findings and 
expert consensus. Moreover, the guidelines are easy to 
understand and apply clinically, and the treatment op-
tions allow for the exercise of judgement by the clinician. 
We hope that the KMAP-SPR 2019 will provide clinicians 
with useful information to help them in making important 
decisions in difficult clinical situations.
This study was supported by the Korean Society for 
Schizophrenia Research and the Korean College of 
Neuropsychopharmacology. This study was presented on 
October 10, 2019 at the 6th Congress of Asian College of 
Neuropsychopharmacology. This research did not re-
ceive any specific grant from funding agencies in the com-
mercial sector.
No potential conflict of interest relevant to this article 
was reported.
Conceptualization: Young-Chul Chung, Chan-Hyung 
Kim. Data acquisition: Jung Suk Lee, Je-Yeon Yun, Shi 
Hyun Kang, Seung Jae Lee, Joon-Ho Choi, Beomwoo 
Nam, and Seung-Hwan Lee. Writing-original draft: Jung 
Suk Lee. Writing-review & editing: Jung Suk Lee, Chan- 
Hyung Kim.
Jung Suk Lee https://orcid.org/0000-0002-5401-1931
Je-Yeon Yun https://orcid.org/0000-0002-5531-2410
Shi Hyun Kang https://orcid.org/0000-0001-8712-5698







1. Field MJ, Lohr KN. Guidelines for clinical practice: from de-
velopment to use. Washington, D.C.:National Academy 
Press;1992.
2. Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, et 
al. Korean medication algorithm for depressive disorders 
2017: third revision. Clin Psychopharmacol Neurosci 2018; 
16:67-87.
3. Woo YS, Bahk WM, Lee JG, Jeong JH, Kim MD, Sohn I, et al. 
Korean medication algorithm project for bipolar disorder 
2018 (KMAP-BP 2018): fourth revision. Clin Psychopharmacol 
Neurosci 2018;16:434-448.
4. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, 
Fischer BA, et al.; Schizophrenia Patient Outcomes Research 
Team (PORT). The 2009 schizophrenia PORT psycho-
pharmacological treatment recommendations and summary 
statements. Schizophr Bull 2010;36:71-93.
5. Barnes TR; Schizophrenia Consensus Group of British 
Association for Psychopharmacology. Evidence-based guide-
lines for the pharmacological treatment of schizophrenia: rec-
ommendations from the British Association for Psycho-
pharmacology. J Psychopharmacol 2011;25:567-620.
6. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, 
Gattaz WF, et al.; World Federation of Societies of Biological 
Psychiatry (WFSBP) Task Force on Treatment Guidelines for 
Schizophrenia. World federation of societies of biological 
psychiatry (WFSBP) guidelines for biological treatment of 
schizophrenia, part 1: update 2012 on the acute treatment of 
schizophrenia and the management of treatment resistance. 
World J Biol Psychiatry 2012;13:318-378.
7. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, 
Killackey E, et al. Royal Australian and New Zealand College 
of Psychiatrists clinical practice guidelines for the manage-
■ Acknowledgments
■ Conflicts of Interest
■ Author Contributions
■ ORCID
 Korean Medication Algorithm for Schizophrenia 2019 393
ment of schizophrenia and related disorders. Aust N Z J 
Psychiatry 2016;50:410-472.
8. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, 
Crismon ML, et al. The Texas Medication Algorithm Project 
antipsychotic algorithm for schizophrenia: 2006 update. J 
Clin Psychiatry 2007;68:1751-1762.
9. National Collaborating Centre for Mental Health (UK). Psychosis 
and schizophrenia in adults: treatment and management. 
London:National Institute for Health and Care Excellence 
(UK);2014.
10. Canuso CM, Battisti WP. Paliperidone extended-release: a re-
view of efficacy and tolerability in schizophrenia, schizo-
affective disorder and bipolar mania. Expert Opin Pharmacother 
2010;11:2557-2567.
11. Chue P, Chue J. A review of paliperidone palmitate. Expert 
Rev Neurother 2012;12:1383-1397.
12. Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, 
Miyake N, et al. Profile of blonanserin for the treatment of 
schizophrenia. Neuropsychiatr Dis Treat 2013;9:587-594.
13. Salgueiro M, Segarra R. Long-acting injectable second-gen-
eration antipsychotics in first-episode psychosis: a narrative 
review. Int Clin Psychopharmacol 2019;34:51-56.
14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck 
RA, Perkins DO, et al.; Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) Investigators. Effectiveness 
of antipsychotic drugs in patients with chronic schizophrenia. 
N Engl J Med 2005;353:1209-1223.
15. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, 
et al. Randomized controlled trial of the effect on quality of 
life of second- vs first-generation antipsychotic drugs in schiz-
ophrenia: Cost Utility of the Latest Antipsychotic Drugs in 
Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 
63:1079-1087.
16. Haddad PM, Brain C, Scott J. Nonadherence with anti-
psychotic medication in schizophrenia: challenges and man-
agement strategies. Patient Relat Outcome Meas 2014;5:43-62.
17. Strejilevich SA, Palatnik A, Avila R, Bustin J, Cassone J, 
Figueroa S, et al. Lack of extrapyramidal side effects predicts 
quality of life in outpatients treated with clozapine or with 
typical antipsychotics. Psychiatry Res 2005;133:277-280.
18. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll 
CU. Relapse prevention in schizophrenia: a systematic re-
view and meta-analysis of second-generation antipsychotics 
versus first-generation antipsychotics. Mol Psychiatry 2013; 
18:53-66.
19. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, 
Graff-Guerrero A, et al. Defining treatment-resistant schizo-
phrenia and response to antipsychotics: a review and recom-
mendation. Psychiatry Res 2012;197:1-6.
20. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clo-
zapine with a second antipsychotic - a meta-analysis. Acta 
Psychiatr Scand 2012;125:15-24.
21. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. 
Amisulpride augmentation in patients with schizophrenia 
partially responsive or unresponsive to clozapine. A random-
ized, double-blind, placebo-controlled trial. Pharmacopsychiatry 
2008;41:24-28.
22. Genç Y, Taner E, Candansayar S. Comparison of clozapine- 
amisulpride and clozapine-quetiapine combinations for pa-
tients with schizophrenia who are partially responsive to clo-
zapine: a single-blind randomized study. Adv Ther 2007;24:1-13.
23. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. 
Aripiprazole augmentation in clozapine-treated patients with 
refractory schizophrenia: an 8-week, randomized, double- 
blind, placebo-controlled trial. J Clin Psychiatry 2008;69: 
720-731.
24. Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Di 
Nardo F, et al. Effect of aripiprazole augmentation of cloza-
pine in schizophrenia: a double-blind, placebo-controlled 
study. Schizophr Res 2011;127:93-99.
25. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, 
et al. Adjunctive risperidone for partially responsive people 
with schizophrenia treated with clozapine. Neuropsycho-
pharmacology 2010;35:2274-2283.
26. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, 
Paing WW, et al. Clozapine augmented with risperidone in 
the treatment of schizophrenia: a randomized, double-blind, 
placebo-controlled trial. Am J Psychiatry 2005;162:130-136.
27. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff 
DC. Risperidone augmentation for schizophrenia partially re-
sponsive to clozapine: a double-blind, placebo-controlled 
trial. Schizophr Res 2007;92:90-94.
28. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, 
Bergmann A, et al.; Clozapine and Risperidone Enhancement 
(CARE) Study Group. Clozapine alone versus clozapine and 
risperidone with refractory schizophrenia. N Engl J Med 
2006;354:472-482.
29. Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, 
Tümüklü M, Yazici MK, et al. A double-blind study of combi-
nation of clozapine with risperidone in patients with schizo-
phrenia: effects on cognition. J Clin Psychiatry 2006;67:1912- 
1919.
30. Sinclair D, Adams CE. Treatment resistant schizophrenia: a 
comprehensive survey of randomised controlled trials. BMC 
Psychiatry 2014;14:253.
31. Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord 
ES, et al. Side effect burden of antipsychotic drugs in real life - 
impact of gender and polypharmacy. Prog Neuropsychophar-
macol Biol Psychiatry 2018;82:263-271.
32. Perkins DO. Adherence to antipsychotic medications. J Clin 
Psychiatry 1999;60 Suppl 21:25-30.
33. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of re-
lapse in schizophrenia. BMC Psychiatry 2013;13:50.
34. Stevens GL, Dawson G, Zummo J. Clinical benefits and im-
pact of early use of long-acting injectable antipsychotics for 
schizophrenia. Early Interv Psychiatry 2016;10:365-377.
394 J.S. Lee, et al.
35. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, 
et al. Antipsychotic drugs versus placebo for relapse pre-
vention in schizophrenia: a systematic review and meta- 
analysis. Lancet 2012;379:2063-2071.
36. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. 
Long-acting injectable versus oral antipsychotics in schizo-
phrenia: a systematic review and meta-analysis of mirror-im-
age studies. J Clin Psychiatry 2013;74:957-965.
37. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, 
Gretchen-Doorly D, et al. Long-acting injectable risperidone 
for relapse prevention and control of breakthrough symptoms 
after a recent first episode of schizophrenia. A randomized 
clinical trial. JAMA Psychiatry 2015;72:822-829.
